Sartorius Stedim Biotech (CHIX:DIMP) Other Long Term Assets: €106 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DIMP Sartorius Stedim Biotech SA CHIX:DIMP
84 GF Score
Price €181.10
GF Value €201.74
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Other Long Term Assets?

Sartorius Stedim Biotech CHIX:DIMP 84 Other Long Term Assets is €106 Mil as of Jun. 2026. GuruFocus rates CHIX:DIMP with a GF Score™ of 84/100 and a GF Value™ of €201.74 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Sartorius Stedim Biotech's other long-term assets for the quarter that ended in Jun. 2026 was €106 Mil.

Sartorius Stedim Biotech's quarterly other long-term assets increased from Dec. 2025 (€98 Mil) to Mar. 2026 (€102 Mil) and increased from Mar. 2026 (€102 Mil) to Jun. 2026 (€106 Mil).

Sartorius Stedim Biotech's annual other long-term assets declined from Dec. 2023 (€103 Mil) to Dec. 2024 (€91 Mil) but then increased from Dec. 2024 (€91 Mil) to Dec. 2025 (€98 Mil).

Sartorius Stedim Biotech Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech Other Long Term Assets Chart

Sartorius Stedim Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.90 88.80 103.30 90.80 97.80

Sartorius Stedim Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 94.10 96.20 97.80 102.00 106.50
CHIX:DIMP
84GF Score
Sartorius Stedim Biotech SA CHIX:DIMP
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius Stedim Biotech Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of €106 Mil mean?
Sartorius Stedim Biotech (CHIX:DIMP) has a Other Long Term Assets of €106 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Sartorius Stedim Biotech and its competitors.
Is Sartorius Stedim Biotech's Other Long Term Assets too high?
Sartorius Stedim Biotech's current Other Long Term Assets is €106 Mil. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Other Long Term Assets compare to ISRG and BDX?
Sartorius Stedim Biotech's Other Long Term Assets of €106 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Medical Devices & Instruments company?
A good Other Long Term Assets depends on the Medical Devices & Instruments industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current Other Long Term Assets is €106 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €201.74, compared to a current price of €181.10 — trading 10.2% below its estimated fair value. The current Other Long Term Assets is €106 Mil. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Other Long Term Assets is €106 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €181.10 is trading 10.2% below its estimated GF Value™ of €201.74. GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.

Key valuation signals for CHIX:DIMP:

  • Other Long Term Assets: €106 Mil
  • GF Value™: €201.74 vs. price of €181.10 (10.2% below fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score

Get the complete analysis for CHIX:DIMP

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€181.10
Price
€201.74
GF Value